Announcements Trials
Browse Landscape

Status

Recruiting 7Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Educational Status 7Standard of Care 5Interviews as Topic 5Cisplatin 5Blood Specimen Collection 5Oxaliplatin 4Surveys and Questionnaires 3Surgical Procedures, Operative 3Specimen Handling 3Patient Navigation 3Observation 3Nivolumab 3Methods 3Magnetic Resonance Imaging 3Fluorouracil 3Early Intervention, Educational 3Dexamethasone 3Carboplatin 3Biopsy 3toripalimab 2sacituzumab govitecan 2pembrolizumab 2lenvatinib 2Transcutaneous Electric Nerve Stimulation 2Radiosurgery 2Practice Guidelines as Topic 2Platinum Compounds 2Paclitaxel 2Music Therapy 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × olverembatinib × 1 year × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡